Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHLR200W mutation (Chuvash polycythemia)

Haematologica

Volumn 97, Issue 2, 2012, Pages 193-200

  Sable, Craig A ^a   Aliyu, Zakari Y ^b,c   Dham, Niti ^a   Nouraie, Mehdi ^b   Sachdev, Vandana ^d   Sidenko, Stanislav ^d   Miasnikova, Galina Y ^e   Polyakova, Lydia A ^e   Sergueeva, Adelina I ^f   Okhotin, Daniel J ^g   Bushuev, Vladimir ^h   Remaley, Alan T ^d   Niu, Xiaomei ^b   Castro, Oswaldo L ^b   Gladwin, Mark T ⁱ   Kato, Gregory J ^d   Prchal, Josef T ^j   Gordeuk, Victor R ^k  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b HOWARD UNIVERSITY   (United States)

^c Taraba State Specialist Hospital   (Nigeria)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e Chuvash Republic Clinical Hospital 2   (Russian Federation)

^f Cheboksary Children's Hospital   (Russian Federation)

^g Russian Research Services   (United States)

^h Chuvash Republic Cardiac Center   (Russian Federation)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

^j UNIVERSITY OF UTAH   (United States)

^k UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

Ferritin; Hypoxia inducible factor; Pulmonary hypertension; Tricuspid regurgitation velocity; VHL

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ERYTHROPOIETIN; FERRITIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD VOLUME; CARDIOVASCULAR PARAMETERS; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLE; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAM; FEMALE; FERRITIN BLOOD LEVEL; GENE; GENE MUTATION; GENOTYPE; HEART VOLUME; HEMATOLOGICAL PARAMETERS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPOXIA; IRON DEFICIENCY; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT; PHLEBOTOMY; POLYCYTHEMIA; PREDICTION; PRESCHOOL CHILD; PREVALENCE; PULSE PRESSURE; RISK FACTOR; SCHOOL CHILD; SYSTOLE; SYSTOLIC BLOOD PRESSURE; TRICUSPID VALVE REGURGITATION; UPREGULATION; VHL GENE;

ADOLESCENT; ADULT; ANEMIA, IRON-DEFICIENCY; ANOXIA; CASE-CONTROL STUDIES; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA; PULMONARY WEDGE PRESSURE; RUSSIA; TRICUSPID VALVE INSUFFICIENCY; UP-REGULATION; VENTRICULAR FUNCTION, LEFT; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84856442980     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.051839     Document Type: Article

References (46)

1. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002; 32(4):614-21.
2. Hickey MM, Lam JC, Bezman NA, Rathmell WK, Simon MC. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. J Clin Invest. 2007; 117(12):3879-89.
3. Bushuev VI, Miasnikova GY, Sergueeva AI, Polyakova LA, Okhotin D, Gaskin PR, et al. Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash poly-cythemia. Haematologica. 2006;91(6):744-9.
4. Gordeuk VR, Sergueeva AI, Miasnikova GY, Okhotin D, Voloshin Y, Choyke PL, et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood. 2004;103(10):3924-32.
5. Smith TG, Talbot NP, Privat C, Rivera-Ch M, Nickol AH, Ratcliffe PJ, et al. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA. 2009;302 (13):1444-50.
6. Hickey MM, Richardson T, Wang T, Mosqueira M, Arguiri E, Yu H, et al. The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibro-sis in mice. J Clin Invest. 2010;120(3):827-39.
7. Semenza GL. Involvement of hypoxia-inducible factor 1 in pulmonary pathophys-iology. Chest. 2005;128(6 Suppl):592S-4S.
8. Percy MJ, Furlow PW, Lucas GS, Li X, Lappin TR, McMullin M F, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med. 2008; 358(2):162-8.
9. Brusselmans K, Compernolle V, Tjwa M, Wiesener MS, Maxwell PH, Collen D, et al. Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest. 2003;111(10):1519-27.
10. Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol. 1985;6(2):359-65.
11. Smith TG, Brooks JT, Balanos GM, Lappin TR, Layton DM, Leedham DL, et al. Mutation of the von Hippel-Lindau gene alters human cardiopulmonary physiology. Adv Exp Med Biol. 2008;605:51-6.
12. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30 (4):393-402.
13. Minamishima YA, Kaelin WG Jr. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science. 2010;329 (5990):407.
14. Smith TG, Balanos GM, Croft QP, Talbot N P, Dorrington KL, Ratcliffe PJ, et al. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol. 2008;586(Pt 24):5999-6005.
15. Soon E, Treacy CM, Toshner MR, MacKenzie-Ross R, Manglam V, Busbridge M, et al. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax. 2011;66(4):326-32.
16. Ruiter G, Lankhorst S, Boonstra A, Postmus PE, Zweegman S, Westerhof N, et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J. 2011;37(6):1386-91.
17. Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JS, et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol. 2011;58(3):300-9.
18. Tay EL, Peset A, Papaphylactou M, Inuzuka R, Alonso-Gonzalez R, Giannakoulas G, et al. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol. 2011;151(3):307-12.
19. Lai WW, Geva T, Shirali GS, Frommelt PC, Humes RA, Brook MM, et al. Guidelines and standards for performance of a pedi-atric echocardiogram: a report from the Task Force of the Pediatric Council of the American Society of Echocardiography. J Am Soc Echocardiogr. 2006;19(12):1413-30.
20. Pettersen MD, Du W, Skeens ME, Humes RA. Regression Equations for Calculation of Z Scores of Cardiac Structures in a Large Cohort of Healthy Infants, Children, and Adolescents: An Echocardiographic Study. J Am Soc Echocardiogr. 2008;21(8):922-34.
21. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002;15(2):167-84.
22. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol. 1997;30(6):1527-33.
23. Niu X, Nouraie M, Campbell A, Rana S, Minniti CP, Sable C, et al. Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease. PLoS One 2009;4(11): e7956.
24. Gordeuk VR, Prchal JT. Vascular complications in Chuvash polycythemia. Semin Thromb Hemost. 2006;32(3):289-94.
25. Bossone E, Rubenfire M, Bach DS, Ricciardi M, Armstrong W F. Range of tricuspid regur-gitation velocity at rest and during exercise in normal adult men: implications for the diagnosis of pulmonary hypertension. J Am Coll Cardiol. 1999;33(6):1662-6.
26. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16): 2250-94.
27. Smith TG, Brooks JT, Balanos GM, Lappin TR, Layton DM, Leedham DL, et al. Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med. 2006;3(7):e290.
28. Lam CS, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redfield MM. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation. 2009;119(20):2663-70.
29. Dham N, Ensing G, Minniti C, Campbell A, Arteta M, Rana S, et al. Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease. Am J Cardiol. 2009;104(5):713-20.
30. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-95.
31. Hill A, Rother RP, Wang X, Morris SM Jr, Quinn-Senger K, Kelly R, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobin-uria. Br J Haematol 2010;149(3):414-25.
32. Minniti CP, Sable C, Campbell A, Rana S, Ensing G, Dham N, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desatura-tion. Haematologica. 2009;94(3):340-7.
33. Morris CR, Vichinsky EP. Pulmonary hypertension in thalassemia. Ann NY Acad Sci. 2010;1202:205-13.
34. Kato GJ, Taylor JG. Pleiotropic effects of intravascular haemolysis on vascular homeostasis. Br J Haematol. 2010;148(5):690-701.
35. Sachdev V, Machado RF, Shizukuda Y, Rao YN, Sidenko S, Ernst I, et al. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol. 2007;49(4):472-9.
36. Semenza GL. Regulation of oxygen home-ostasis by hypoxia-inducible factor 1. Physiology (Bethesda). 2009;24:97-106.
37. Safran M, Kaelin WG Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest. 2003;111(6):779-83.
38. Boutin AT, Weidemann A, Fu Z, Mesropian L, Gradin K, Jamora C, et al. Epidermal sensing of oxygen is essential for systemic hypoxic response. Cell. 2008;133(2):223-34.
39. Ge RL, Ma RY, Bao HH, Zhao XP, Qi HN. Changes of cardiac structure and function in pediatric patients with high altitude pulmonary hypertension in Tibet. High Alt Med Biol. 2009;10(3):247-52.
40. Reeves JT, Grover RF. Insights by Peruvian scientists into the pathogenesis of human chronic hypoxic pulmonary hypertension. J Appl Physiol. 2005;98(1):384-9.
41. Formenti F, Beer PA, Croft QP, Dorrington KL, Gale D P, Lappin TR, et al. Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2alpha gain-of-function mutation. FASEB J. 2011;25(6):2001-11.
42. Park SS, Bae I, Lee YJ. Flavonoids-induced accumulation of hypoxia-inducible factor (HIF)-1alpha/2alpha is mediated through chelation of iron. J Cell Biochem. 2008;103 (6):1989-98.
43. Chan DA, Sutphin PD, Denko NC, Giaccia AJ. Role of prolyl hydroxylation in onco-genically stabilized hypoxia-inducible fac-tor-1alpha. J Biol Chem. 2002;277(42): 40112-7.
44. Sanchez M, Galy B, Muckenthaler MU, Hentze MW. Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat Struct Mol Biol. 2007;14(5):420-6.
45. Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease. Pediatrics. 2008;121(4):777-82.
46. Nakamura A, Kasamatsu N, Hashizume I, Shirai T, Hanzawa S, Momiki S, et al. Effects of hemoglobin on pulmonary arterial pressure and pulmonary vascular resistance in patients with chronic emphysema. Respiration. 2000;67(5):502-6.